3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inducción de remisión con gentamicina y vancomicina oral en enfermedad inflamatoria intestinal de inicio temprano Translated title: Very early onset inflammatory bowel disease remission induced with oral gentamicin and vancomycin

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen La enfermedad inflamatoria intestinal de inicio temprano se manifiesta en pacientes pediátricos antes de los 6 años de edad. Habitualmente se asocia a diversas causas, siendo descrita frecuentemente la disbiosis como factor desencadenante. Esta población presenta comúnmente refractariedad a los tratamientos inmunosupresores más empleados. Presentamos el caso de un paciente con colitis no clasificable y corticodependiente de un año de evolución ingresado en nuestro centro que no había respondido a terapia inmunosupresora intensificada. Se plantea terapia con antibióticos orales como inducción de la remisión del brote de actividad en combinación con su tratamiento inmunomodulador habitual. Si bien inicialmente se obtiene la remisión clínica, el paciente experimenta posteriormente al alta un nuevo brote de actividad siendo necesaria una segunda reinducción con antibióticos que no resulta eficaz, motivando su suspensión.

          Translated abstract

          Abstract Very early onset inflammatory bowel disease occurs in children under 6 years age. It is frequently associated to a diverse ethiology, dysbiosis being usually described as a triggering factor. Commonly, this population is highly resilient to inmmunosuppressant therapies. We report here a medical case of a patient diagnosed with unclassified and steroid-dependent colitis, with a year of evolution, who had no responded to intensified therapy at home, and, therefore, was hospitalized at our centre. Treatment with oral antibiotics was intended as remission induction in combination with his usual inmmunomodulator treatment. Although clinical remission was observed at first stage, a new activity outbreak emerged requiring a second round of antibiotics therapy, which was unsuccessful and currently withdrawned.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: not found
          • Article: not found

          Antibiotics in IBD: Still a Role in the Biological Era?

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Oral Vancomycin and Gentamicin for Treatment of Very Early Onset Inflammatory Bowel Disease

            Background: The pathogenesis of inflammatory bowel disease (IBD) is complex and involves the contribution of genetic and environmental factors. Many patients with very early onset IBD are difficult to treat. The current antibiotic medication that targets gram-negative and anaerobic bacteria provides only moderate efficacy in subsets of patients with IBD. Methods: We report a case series of 5 children with a mean age of 1.6 years (range 6 months to 2.7 years) during IBD onset, who were previously refractory to standard treatments and who received oral vancomycin with or without gentamicin. Results: Four out of 5 children demonstrated substantial therapeutic effect, and the effect was sustained in 3 children over a follow-up period of 12-33 months. Conclusion: Our findings are consistent with model systems and suggest that randomized trials are required to establish whether a change in therapeutic paradigm, that is, targeting gram-positive bacteria with nonabsorbable antibiotics, may have therapeutic benefits.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Pediatric inflammatory bowel disease Special considerations

                Bookmark

                Author and article information

                Journal
                ofil
                Revista de la OFIL
                Rev. OFIL·ILAPHAR
                Organización de Farmacéuticos Ibero-Latinoamericanos (Madrid, Madrid, Spain )
                1131-9429
                1699-714X
                June 2022
                : 32
                : 2
                : 203-205
                Affiliations
                [1] Madrid orgnameHospital 12 de Octubre orgdiv1Servicio de Farmacia España bssanz@ 123456salud.madrid.org
                Article
                S1699-714X2022000200014 S1699-714X(22)03200200014
                10.4321/s1699-714x2022000200014
                d7cf3e63-dd4c-43d9-908e-d0fb3cc53b31

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 02 November 2020
                : 20 October 2020
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 5, Pages: 3
                Product

                SciELO Spain

                Categories
                Casos Clínicos

                gentamicina,vancomycin,gentamicin,Enfermedad inflamatoria intestinal,vancomicina,Inflammatory bowel disease

                Comments

                Comment on this article